SAGE Therapeutics Inc (SAGE) : Casdin Capital scooped up 45,989 additional shares in SAGE Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 9, 2016. The investment management firm now holds a total of 189,000 shares of SAGE Therapeutics Inc which is valued at $6,065,010.SAGE Therapeutics Inc makes up approximately 7.43% of Casdin Capital’s portfolio.
Other Hedge Funds, Including , Tekla Capital Management boosted its stake in SAGE in the latest quarter, The investment management firm added 49,000 additional shares and now holds a total of 146,800 shares of SAGE Therapeutics Inc which is valued at $4,710,812. SAGE Therapeutics Inc makes up approx 0.21% of Tekla Capital Management’s portfolio.Swiss National Bank boosted its stake in SAGE in the latest quarter, The investment management firm added 15,600 additional shares and now holds a total of 33,100 shares of SAGE Therapeutics Inc which is valued at $1,119,773.Rhumbline Advisers boosted its stake in SAGE in the latest quarter, The investment management firm added 1,755 additional shares and now holds a total of 15,290 shares of SAGE Therapeutics Inc which is valued at $517,261.Candriam Luxembourg S.c.a. reduced its stake in SAGE by selling 7,200 shares or 9.45% in the most recent quarter. The Hedge Fund company now holds 69,000 shares of SAGE which is valued at $2,600,610. SAGE Therapeutics Inc makes up approx 0.06% of Candriam Luxembourg S.c.a.’s portfolio.
SAGE Therapeutics Inc opened for trading at $31.46 and hit $32.45 on the upside on Friday, eventually ending the session at $32.09, with a gain of 1.36% or 0.43 points. The heightened volatility saw the trading volume jump to 3,17,680 shares. Company has a market cap of $1,029 M.
Many Wall Street Analysts have commented on SAGE Therapeutics Inc. SAGE Therapeutics Inc was Initiated by Goldman to “Neutral” on Mar 30, 2016. Lake Street Initiated SAGE Therapeutics Inc on Mar 11, 2016 to “Buy”, Price Target of the shares are set at $90.
SAGE Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening rare central nervous system (CNS) disorders. The Company’s lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline. The Company has submitted investigational new drug (IND) for SAGE-547 for the treatment of SRSE with the United States Food and Drug Administration. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is being developed as an adjunctive IV therapy for the treatment of status epilepticus patients.